scholarly journals Targeted radionuclide therapy frontiers in theranostics

10.2741/4569 ◽  
2017 ◽  
Vol 22 (10) ◽  
pp. 1750-1759 ◽  
Author(s):  
Francesca Gallivanone
Keyword(s):  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy

Organs dosimetry in targeted radionuclide therapy

2021 ◽  
pp. 109668
Author(s):  
Meshari Alnaaimi ◽  
Abdelmoneim Sulieman ◽  
Mohammed Alkhorayef ◽  
Hasan Salah ◽  
Musa Alduaij ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy

scholarly journals Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

2021 ◽  
Vol 14 (7) ◽  
pp. 626
Author(s):  
Julie Bolcaen ◽  
Shankari Nair ◽  
Cathryn H. S. Driver ◽  
Tebatso M. G. Boshomane ◽  
Thomas Ebenhan ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Receptor Tyrosine Kinase ◽  
Tyrosine Kinases ◽  
Radionuclide Therapy ◽  
Kinase Inhibitors ◽  
Nuclear Imaging ◽  
Therapy Resistance ◽  
Targeted Radionuclide Therapy ◽  
Therapy Strategy ◽  
Dismal Prognosis

Glioblastoma (GB) remains the most fatal brain tumor characterized by a high infiltration rate and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is common in GB, which subsequently leads to the activation of many downstream pathways that have a critical impact on tumor progression and therapy resistance. Therefore, receptor tyrosine kinase inhibitors (RTKIs) have been investigated to improve the dismal prognosis of GB in an effort to evolve into a personalized targeted therapy strategy with a better treatment outcome. Numerous RTKIs have been approved in the clinic and several radiopharmaceuticals are part of (pre)clinical trials as a non-invasive method to identify patients who could benefit from RTKI. The latter opens up the scope for theranostic applications. In this review, the present status of RTKIs for the treatment, nuclear imaging and targeted radionuclide therapy of GB is presented. The focus will be on seven tyrosine kinase receptors, based on their central role in GB: EGFR, VEGFR, MET, PDGFR, FGFR, Eph receptor and IGF1R. Finally, by way of analyzing structural and physiological characteristics of the TKIs with promising clinical trial results, four small molecule RTKIs were selected based on their potential to become new therapeutic GB radiopharmaceuticals.

scholarly journals Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Pharmaceutics ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 599
Author(s):  
Stephen Ahenkorah ◽  
Irwin Cassells ◽  
Christophe M. Deroose ◽  
Thomas Cardinaels ◽  
Andrew R. Burgoyne ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Radionuclide Therapy ◽  
Chemical Properties ◽  
High Energy ◽  
Magic Bullet ◽  
Targeted Radionuclide Therapy ◽  
Energy Photon ◽  
Normal Tissues ◽  
Preclinical And Clinical Studies ◽  
Alpha Therapy

In contrast to external high energy photon or proton therapy, targeted radionuclide therapy (TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and all its metastases, resulting in less collateral damage to normal tissues. The α-emitting radionuclide bismuth-213 (213Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with 213Bi are discussed in this review, covering the entire chain from radionuclide production to bedside. First, the radionuclide properties and production of 225Ac and its daughter 213Bi are discussed, followed by the fundamental chemical properties of bismuth. Next, an overview of available acyclic and macrocyclic bifunctional chelators for bismuth and general considerations for designing a 213Bi-radiopharmaceutical are provided. Finally, we provide an overview of preclinical and clinical studies involving 213Bi-radiopharmaceuticals, as well as the future perspectives of this promising cancer treatment option.

Treatment Planning for Molecular Targeted Radionuclide Therapy

2002 ◽  
Vol 17 (3) ◽  
pp. 267-280 ◽  
Author(s):  
Christine L. Hartmann Siantar ◽  
Kai Vetter ◽  
Gerald L. DeNardo ◽  
Sally J. DeNardo
Keyword(s):  
Treatment Planning ◽  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy

scholarly journals Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody

Theranostics ◽  
2014 ◽  
Vol 4 (7) ◽  
pp. 708-720 ◽  
Author(s):  
Matthias D'Huyvetter ◽  
Cécile Vincke ◽  
Catarina Xavier ◽  
An Aerts ◽  
Nathalie Impens ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy

Safety of Fibroblast Activation Protein–Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Serkan Kuyumcu ◽  
Bilal Kovan ◽  
Yasemin Sanli ◽  
Fikret Buyukkaya ◽  
Duygu Has Simsek ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Low Dose ◽  
Fibroblast Activation Protein ◽  
Targeted Radionuclide Therapy ◽  
Fibroblast Activation

Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma

1996 ◽  
Vol 37 (5) ◽  
pp. 241-246 ◽  
Author(s):  
L. Moe ◽  
M. Boysen ◽  
M. Aas ◽  
L. Lønaas ◽  
H. Gamlem ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy ◽  
Canine Osteosarcoma
Sign in / Sign up

Export Citation Format

Share Document